Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-281-5 | CAS number: 137-16-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu./o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 04 Aug - 05 Dec 2013
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 014
- Report date:
- 2014
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Version / remarks:
- adopted 22 January 2001
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.3700 (Prenatal Developmental Toxicity Study)
- Version / remarks:
- adopted August 1998
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: Japanese Ministry of Agriculture, Forestry and Fisheries Testing guidelines for Toxicology studies, 12 NohSa No 8147, 24 November 2000
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
Test material
- Reference substance name:
- Sodium N-lauroylsarcosinate
- EC Number:
- 205-281-5
- EC Name:
- Sodium N-lauroylsarcosinate
- Cas Number:
- 137-16-6
- Molecular formula:
- C15H29NO3.Na
- IUPAC Name:
- sodium [dodecanoyl(methyl)amino]acetate
- Test material form:
- solid: particulate/powder
- Remarks:
- migrated information: powder
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Remarks:
- Crl:CD® (SD)IGS BR
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River, Margate, UK
- Age at study initiation: not specified in report, animals purchased time-mated
- Weight at study initiation: 197-268 g (females on arrival, prior to GD3)
- Housing: individual in solid-floor propylene cages with stainless steel lids in a single air-conditioned room, bedding with softfood flakes
- Diet: pellet diet (Rodent 2018C Teklad Global Certified Diet, Harlan; Oxon; UK) ad libitum, environmental enrichment provided in the form of wooden chew blocks and cardboard fun tunnels
- Water: ad libitum
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3
- Humidity (%): 50 ± 20
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: 04 Aug 2013 (first day of treatment) To: 22 Aug 2013 (final day of necropsy)
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Remarks:
- distilled water
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
the test item was prepared at the appropriate concentrations as a solution in distilled water.
VEHICLE
- Concentration in vehicle: 6, 20 and 50 mg/mL
- Amount of vehicle (if gavage): 5 mL/kg - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The test item concentration in the test samples was determined by high performance liquid chromatography (HPLC/UV) using an external standard technique.The formulations investigated during the study were found to comprise test item in the range of 101% to 104% and, thus, the required content limit ± 10% with reference to the nominal content was met. The test item was found to be stable in the formulations when kept for twenty one days in the refrigerator due to results which met the variation limit of 10% from the time-zero mean. Thus, the results indicate the accurate use of the test item and distilled water as vehicle during this study. The formulations were found to be homogeneously prepared, and sufficient formulation stability under storage conditions was approved.
- Details on mating procedure:
- - Impregnation procedure: purchased timed pregnant
- Duration of treatment / exposure:
- Gestation Day 5-19
- Frequency of treatment:
- daily, 7 days/week
- Duration of test:
- until Gestation Day 20 (terminal sacrifice)
Doses / concentrations
- Remarks:
- Doses / Concentrations:
30, 100 and 250 mg/kg bw/day
Basis:
actual ingested
- No. of animals per sex per dose:
- 24 P females
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: The dose levels were chosen based on previous toxicity data.
Examinations
- Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: once daily
- Cage side observations checked included: following arrival, all animals were examined for overt signs of toxicity, ill-health or behavioural changes once daily during the gestation period. An additional observation was also performed five hours after dosing during the normal working week. All observations were recorded.
DETAILED CLINICAL OBSERVATIONS: No
BODY WEIGHT: Yes
- Time schedule for examinations: individual body weights were recorded for each surviving individual animal at Day 3, 5, 6, 7, 8, 11, 14, 17 and 20 (termination kill) of gestation.
FOOD CONSUMPTION AND COMPOUND INTAKE: Yes
- Food consumption for each animal determined: Yes, at Day 3, 5, 8, 11, 14, 17 and 20 of gestation.
WATER CONSUMPTION AND COMPOUND INTAKE: Yes
- Time schedule for examinations: daily by visual inspection of water bottles
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day # 20
- Organs examined: ovaries and uteri of pregnant females, full external and internal examination; any macroscopic abnormalities were recorded; the stomach was retained from all females - Ovaries and uterine content:
- The ovaries and uterine content were examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes
- Other: fetal sex, placental weight, position and type of intrauterine implantation - Fetal examinations:
- - External examinations: Yes: [all per litter]
- Soft tissue examinations: Yes: [all per litter]
- Skeletal examinations: Yes: [all per litter]
- Head examinations: No - Statistics:
- Group mean values were calculated to include data from all females with live fetuses on Day 20 of gestation. As the litter was the standard unit of assessment, values were first calculated within the litter, and group mean values represent the mean of these individual litter values.
The following parameters were analyzed statistically, where appropriate, using the test methods outlined below:
Female body weight change, food consumption and gravid uterus weight: Bartlett´s test for homogeneity of variance and one way analysis of variance, followed by Dunnett´s multiple comparison test or, if unequal variances were observed, an alternative multiple comparison test.
All caesarean necropsy parameters and fetal parameters: Kruskal-Wallis non-parametric analysis of variance; and a subsequent pairwise analysis of control values against treated values using the Mann-Whitney ‘U’ test, where significance was seen.
Fetal evaluation parameters, including skeletal or visceral findings: Kruskal-Wallis non-parametric analysis of variance and Mann-Whitney ‘U’ test.
Probability values (p) demonstrating different levels of significance were chosen as follows:
p<0.001 ***
p<0.01 **
p<0.05 *
p>=0.05 (not significant) - Indices:
- Pre implantation loss: [(number of corpora lutea-number of implantations) / number of corpora lutea] x 100;
Post-implantation loss: [(number of implantations–number of live foetuses)/number of implantations] x 100;
Sex ratio: % male fetuses (sex ratio)= [Number of male foetuses / Total number of foetuses] x 100
Results and discussion
Results: maternal animals
General toxicity (maternal animals)
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- 250 mg/kg bw/day: the female found dead on Day 10 did not show any clinical signs prior to Day 10. The female found dead on Day 18 had noisy respiration on Days 10 and 17 and increased salivation and pilo-erection on Day 17.
5/22 females showed incidences of increased salivation between Days 10 and 19 and 3/22 females also showed noisy respiration on either Day 6 or 7.
100 mg/kg bw/day: 1/24 females showed increased salivation on Day 18 and 1/24 females had noisy respiration on Day 13.
Observations of this nature are commonly observed following the oral administration of an unpalatable or irritant test item formulation and are considered not to represent true systemic toxicity.
Control: 1/24 females had fur loss on Day 18. In the absence of treatment this was considered of no toxicological importance. - Dermal irritation (if dermal study):
- not examined
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- 250 mg/kg bw/d: One female treated was found dead on Day 10 and another female was found dead on Day 18.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- 250 mg/kg bw/day: body weight gain of the females was lower throughout the treatment period and cumulative body weight gain to Day 14 (where body weight is not greatly influenced by the weight of the gravid uterus) was 24% lower than the corresponding control value. By termination on Day 20, cumulative body weight gain was 15% lower than the corresponding control values. When final body weight was adjusted for the gravid uterus, an overall body weight gain reduction was evident during gestation.
100 mg/kg bw/day: females showed a slight reduction in cumulative body weight gain from Day 7 onwards. When final body weight was adjusted for the gravid uterus, an overall body weight gain reduction was evident during gestation. - Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- 250 mg/kg bw/day: females showed a reduction in food consumption throughout the treatment period. Statistically significant reductions were evident between Days 8 and 11 (p < 0.001) and Days 14-17 (p< 0.05) compared with the control group.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Description (incidence and severity):
- The female treated with 250 mg/kg bw/day that was found dead on Day 10 had gaseous distention in the stomach and gastro-intestinal tract. The other interim death female had sloughing on the non-glandular region of the stomach, seven dead foetuses in the right uterine horn and five dead foetuses in the left uterine horn. The remaining females treated with 250 mg/kg bw/day that were terminated on Day 20 all had sloughing on the non-glandular region of the stomach.
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- not examined
- Histopathological findings: neoplastic:
- not examined
Maternal developmental toxicity
- Pre- and post-implantation loss:
- no effects observed
- Total litter losses by resorption:
- no effects observed
- Early or late resorptions:
- no effects observed
- Dead fetuses:
- no effects observed
- Changes in pregnancy duration:
- not examined
- Description (incidence and severity):
- Migrated Data from removed field(s)
Field "Effects on pregnancy duration" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsMaternalAnimals.MaternalDevelopmentalToxicity.EffectsOnPregnancyDuration): not examined - Changes in number of pregnant:
- not examined
Effect levels (maternal animals)
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- 30 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- other: maternal toxicity
- Dose descriptor:
- LOAEL
- Effect level:
- 100 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- other: maternal toxicity
Results (fetuses)
- Fetal body weight changes:
- no effects observed
- Description (incidence and severity):
- Migrated Data from removed field(s)
Field "Fetal/pup body weight changes" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsFetuses.FetalPupBodyWeightChanges): not examined - Reduction in number of live offspring:
- no effects observed
- Changes in sex ratio:
- no effects observed
- Changes in litter size and weights:
- effects observed, treatment-related
- Description (incidence and severity):
- Females from all treatment groups showed a statistically significant reduction (p<0.05 - p<0.01) in the number of corpora lutea. The intergroup differences did not show a true dose related response and were considered to be incidental and unrelated to treatment due to ovulation and mating occurring prior to the administration of the test item. As a consequence of incidentally lower number of corpora lutea in treated females litter size was statistically significantly reduced (p<0.05) in all treated females. The intergroup differences did not show a true dose related response and in the absence of any effect on post-implantation loss and mean fetal weights it supports the assumption that the intergroup differences in litter size was considered to be incidental and of no toxicological importance.
- Changes in postnatal survival:
- not specified
- External malformations:
- no effects observed
- Skeletal malformations:
- no effects observed
- Visceral malformations:
- no effects observed
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:no effects
Details on embryotoxic / teratogenic effects:
There was no obvious adverse effect of maternal treatment on litter data as assessed by the mean number of implantations, early and late embryonic/fetal deaths and live fetuses or sex ratio, as assessed by percentage male.
For all dose groups, there were no significant treatment-related trends in the proportion of fetuses (or litters) with evidence of visceral or skeletal anomalies. The types of external, visceral and skeletal anomalies were those commonly observed for this type of study. There were no findings that were considered to represent any known malformations.
Effect levels (fetuses)
- Dose descriptor:
- NOEL
- Effect level:
- 250 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- other: No adverse effect on developmental toxicity observed at the highest tested dose level.
Fetal abnormalities
- Abnormalities:
- not specified
Overall developmental toxicity
- Developmental effects observed:
- not specified
Any other information on results incl. tables
All treated females showed statistically significant reduction of corpora lutea and in consequence reduced litter sizes. The intergroup differences did not show a true dose related response and were considered to be incidental and unrelated due to ovulation and mating occurring prior to the administration of the test item starting on GD5. The absence of any effect on post-implantation loss and mean fetal weights supports the assumption that these intergroup differences in litter size were considered to be incidental and of no toxicological importance. Foetuses of the 250 mg/kg bw/day group showed a statistically significant increase in the percent of foetuses showing one or more ossified forepaw phalanges. Due to the isolated occurrence of this observation it is not considered to be a true developmental effect and it is therefore of no biological importance.
Table A: Group Mean Litter Data Values (Mean ± SD)
Dose Level (mg/kg bw/day) |
Number of Litters |
Number of Corpora Lutea |
Number of Implants |
Number of Embryonic/Fetal Deaths |
Number of Live Implants |
||||
Early |
Late |
Total |
Male |
Female |
Total |
||||
0 (control) |
23 |
15.2 ± 1.8 |
13.9 ± 1.6 |
0.1 ± 0.3 |
0.1 ± 0.6 |
0.3 ± 0.7 |
6.9 ± 1.8 |
6.8 ± 1.9 |
13.7 ± 2.1 |
30 |
21 |
14.3* ± 1.8 |
13.1 ± 2.0 |
1.0 ± 2.4 |
0.1 ± 0.4 |
1.0 ± 2.5 |
6.0 ± 2.7 |
6.1 ± 2.4 |
12.1* ± 3.4 |
100 |
24 |
13.7* ± 1.9 |
13.0 ± 1.8 |
0.6 ± 1.3 |
0.2 ± 0.7 |
0.8 ± 1.4 |
6.5 ± 2.1 |
5.6 ± 1.7 |
12.1* ± 2.5 |
250 |
22 |
13.9** ± 1.2 |
13.2 ± 1.1 |
0.5 ± 1.4 |
0.2 ± 0.9 |
0.7 ± 1.6 |
6.5 ± 2.0 |
6.0 ± 1.9 |
12.5* ± 2.2 |
p<0.001 ***
p<0.01 **
p<0.05 *
p≥0.05 not significant
Table A: Group Mean Litter Data Values (continued) (Mean ± SD)
Dose Level (mg/kg bw/day) |
Implantation Loss (%) |
Male foetuses (%) |
Mean Male Fetal Weight (g) |
Mean Female Fetal Weight (g) |
Mean Fetal Weight (g) |
Mean Placental Weight (g) |
Litter Weight (g) |
Total Placental Weight (g) |
|
Pre |
Post |
||||||||
0 (control) |
8.4 ± 7.4 |
2.3 ± 7.2 |
50.4 ± 11.3 |
4.117 ± 0.260 |
3.935 ± 0.264 |
4.026 ± 0.257 |
0.564 ± 0.047 |
54.883 ± 8.672 |
7.667 ± 1.141 |
30 |
8.0 ± 10.0 |
8.4 ± 19.4 |
48.6 ± 15.2 |
4.152 ± 0.405 |
3.881 ± 0.372 |
4.005 ± 0.365 |
0.578 ± 0.155 |
48.345 ± 13.761 |
6.729 ± 1.942 |
100 |
5.0 ± 5.2 |
6.9 ± 12.2 |
53.7 ± 12.8 |
4.166 ± 0.339 |
3.886 ± 0.269 |
4.036 ± 0.289 |
0.542 ± 0.060 |
49.142 ± 11.318 |
6.540 ± 1.503 |
250 |
4.8 ± 5.3 |
5.5 ± 12.5 |
52.2 ± 13.7 |
4.221 ± 0.347 |
4.033 ± 0.327 |
4.126 ± 0.320 |
0.540 ± 0.057 |
51.237 ± 8.200 |
6.744 ± 1.369 |
Table B: Group Mean Cumulative Body Weight Change Values (Mean ± SD)
Dose Level (mg/kg bw/day) |
Number of Animals |
Cumulative Body Weight Change (g) from GD5 |
||||||
GD6 |
GD7 |
GD8 |
GD11 |
GD14 |
GD17 |
GD20 |
||
0 (control) |
23 |
4.0 ± 3.4 |
7.6 ± 3.7 |
13.0 ± 5.1 |
33.6 ± 6.6 |
51.6 ± 8.1 |
82.3 ± 10.4 |
127.8 ± 14.9 |
30 |
21 |
5.1 ± 5.4 |
7.1 ± 8.2 |
12.9 ± 10.2 |
34.0 ± 12.9 |
53.5 ± 15.5 |
82.2 ± 19.2 |
127.0 ± 23.4 |
100 |
24 |
2.3 ± 5.3 |
6.1 ± 5.5 |
8.8 ± 7.5 |
27.6 ± 9.9 |
44.8 ± 13.8 |
74.2* ± 12.4 |
114.3* ± 17.2 |
250 |
24/22+ |
0.5 ± 9.0 |
3.6 ± 10.1 |
7.3 ± 11.2 |
21.7** ± 14.6 |
39.3* ± 17.8 |
68.2** ± 20.0 |
109.1** ± 24.7 |
+ = n=23 on GD10, n=22
on GD18
p<0.001 ***
p<0.01 **
p<0.05 *
p≥0.05 not significant
Table C: Group Mean Gravid Uterus Weight , Adjusted Body Weight and Body Weight Change Values (Mean ± SD)
Dose Level (mg/kg bw/day) |
Number of Animals |
Body Weight (g) on Days of Gestation |
Body Weight Change (g) during GD5-20 |
Gravid Uterus Weight (g) |
Adjusted Body Weight (g) GD20 |
Adjusted Body Weight (g) Change GD5-20 |
|
GD5 |
GD20 |
||||||
0 (control) |
23 |
262.6 ± 20.6 |
390.4 ± 29.8 |
127.8 ± 14.9 |
84.663 ± 12.502 |
305.8 ± 23.4 |
43.2 ± 8.2 |
30 |
21 |
261.7 ± 12.9 |
288.7 ± 27.3 |
127.0 ± 23.4 |
75.544 ± 18.733 |
313.2 ± 28.6 |
51.5 ± 22.7 |
100 |
24 |
260.6 ± 14.4 |
374.9 ± 24.8 |
114.3** ± 17.2 |
75.893 ± 15.615 |
299.0 ± 20.7 |
38.4* ± 14.6 |
250 |
24/22+ |
257.6 ± 15.5 |
368.1 ± 32.4 |
109.1** ± 24.7 |
77.535 ± 11.935 |
290.6 ± 25.0 |
31.6** ± 18.7 |
+ = n=23 on GD10, n=22
on GD18
p<0.001 ***
p<0.01 **
p<0.05 *
p≥0.05 not significant
Table D: Group Mean Food Consumption Values (Mean ± SD)
Dose Level (mg/kg bw/day) |
Number of Animals |
Food Consumption (g/rat/day) between Days of Gestation |
|||||
3-5 |
5-8 |
8-11 |
11-14 |
14-17 |
17-20 |
||
0 (control) |
23 |
23.0 ± 3.1 |
25.1 ± 2.5 |
26.5 ± 2.6 |
26.1 ± 2.8 |
25.9 ± 3.0 |
28.0 ± 2.4 |
30 |
21 |
23.6 ± 3.7 |
24.5 ± 3.9 |
27.1 ± 3.7 |
26.5 ± 3.7 |
26.0 ± 4.2 |
28.7 ± 3.8 |
100 |
24 |
22.8 ± 2.9 |
23.9 ± 2.8 |
24.9 ± 3.3 |
24.6 ± 3.7 |
24.5 ± 3.4 |
27.5 ± 2.9 |
250 |
24/22+# |
22.3 ± 3.4 |
22.4 ± 5.3 |
21.5*** ± 4.7 |
23.3 ± 4.3 |
22.6* ± 4.2 |
25.4 ± 3.8 |
+ = n=23 on GD10, n=22
on GD18
# = Food consumption not performed on GD 8 and 11 for female Nos. 85 to
90 due to technician error
p<0.001 ***
p<0.01 **
p<0.05 *
p≥0.05 not significant
In conclusion the oral administration of the test substance to pregnant rats by oral gavage during gestation at dose levels of 30, 100 and 250 mg/kg bw/day resulted in treatment related effects detected in females treated with 250 and 100 mg/kg bw/day. The NOAEL was therefore considered to be 30 mg/kg bw/day.
No toxicological significant changes were detected in the offspring parameters measured. The NOEL for developmental toxicity was therefore considered to be 250 mg/kg bw/day.
Applicant's summary and conclusion
- Conclusions:
- Under the conditions of the study the test substance did not induce any treatment-related biologically relevant malformations in the developing unborn organism in the presence of maternal toxicity. Therefore, the test substance does not meet the criteria for classification for prenatal developmental toxicity according to Regulation (EC) No 1272/2008. The available data is thus conclusive but not sufficient for classification.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)